Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Spironolactone

FDA-approved product (tablet, oral), marketed as Aldactone, Carospir, Spironolactone.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Spironolactone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Ascites
  • Cardiovascular disease
  • Cirrhosis of liver
  • Congestive heart failure
  • Edema
  • Essential hypertension
  • Heart failure
  • Hepatic fibrosis
  • Hypertension
  • Myocardial infarction
  • Nephrotic syndrome
  • Preeclampsia
  • Primary hyperaldosteronism

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Aldosterone antagonists
FDA pharmacologic class
Aldosterone Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis33.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Spironolactone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Spironolactone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effect of Aldosterone Blockade on Arterial Compliance

    NCT01089309 · start 2004-05

    Registered record
    Registry ID
    NCT01089309
    Conditions
    Arterial Stiffness; Arterial Elasticity
    Interventions
    Spironolactone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-05
    Completion
    2007-06
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArterial Stiffness; Arterial Elasticity
    InterventionSpironolactone
    PhasePhase 4
    Registry statusCompleted

  • Improving Outcomes in Patients With Kidney Disease Due to Diabetes

    NCT00381134 · start 2003-07

    Registered record
    Registry ID
    NCT00381134
    Conditions
    Diabetes; Kidney Disease; Hypertension
    Interventions
    losartan 100 mg orally once daily; spironolactone 25 mg orally once daily; placebo once orally once daily
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-07
    Completion
    2006-12
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes; Kidney Disease; Hypertension
    Interventionlosartan 100 mg orally once daily; spironolactone 25 mg orally once daily; placebo once orally once daily
    PhasePhase 2
    Registry statusCompleted

  • The Effects of Clonidine on the Diuretic Response in Cirrhotic Patients

    NCT00356226 · start 2000-10

    Registered record
    Registry ID
    NCT00356226
    Conditions
    Ascitic Cirrhosis; Hyperactivation of Sympathetic Nervous System
    Interventions
    clonidine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2000-10
    Completion
    Not recorded
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAscitic Cirrhosis; Hyperactivation of Sympathetic Nervous System
    Interventionclonidine
    PhaseNot applicable
    Registry statusCompleted

  • Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome

    NCT02378805 · start 1995-07

    Registered record
    Registry ID
    NCT02378805
    Conditions
    Alport Syndrome; Hereditary Kidney Disease; Pediatric Kidney Disease; Thin Basement Membrane Disease; Familial Benign Hematuria
    Interventions
    ACE-inhibitor; Angiotensin-receptor blocker (ARB); HMG-Coenzyme inhibitor (statin); Spironolactone or Finerenone; Paricalcitol; SGLT2 inhibitor
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    1995-07
    Completion
    2036-03-01
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlport Syndrome; Hereditary Kidney Disease; Pediatric Kidney Disease; Thin Basement Membrane Disease +1 more
    InterventionACE-inhibitor; Angiotensin-receptor blocker (ARB); HMG-Coenzyme inhibitor (statin); Spironolactone or Finerenone +2 more
    PhaseNot recorded
    Registry statusRecruiting

  • Cardiovascular Protective Effect of Spironolactone in Hemodialysis

    NCT00277693

    Registered record
    Registry ID
    NCT00277693
    Conditions
    Hemodialysis
    Interventions
    Spironolactone (drug)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHemodialysis
    InterventionSpironolactone (drug)
    PhasePhase 4
    Registry statusUnknown